The Respiratory Syncytial Virus Fusion Protein and Neutrophils Mediate the Airway Mucin Response to Pathogenic Respiratory Syncytial Virus Infection

Kate L. Stokes, Emory University
Michael G. Currier, Emory University
Kaori Sakamoto, University of Georgia, Athens
Sujin Lee, Emory University
Peter L. Collins, National Institute of Allergy and Infectious Diseases
Richard Karl Plemper, Emory University
Martin L. Moore, Emory University

Journal Title: Journal of Virology
Volume: Volume 87, Number 18
Publisher: American Society for Microbiology | 2013-09, Pages 10070-10082
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01347-13
Permanent URL: http://pid.emory.edu/ark:/25593/fk7rc

Final published version: http://jvi.asm.org/content/87/18/10070

Copyright information:
© 2013, American Society for Microbiology. All Rights Reserved.

Accessed January 9, 2020 5:01 AM EST
The Respiratory Syncytial Virus Fusion Protein and Neutrophils Mediate the Airway Mucin Response to Pathogenic Respiratory Syncytial Virus Infection

Kate L. Stokes,a,b Michael G. Currier,a,b Kaori Sakamoto,c Sujin Lee,a,b Peter L. Collins,d Richard K. Plemper,a,b Martin L. Moorea,b
Department of Pediatrics, Emory University, Atlanta, Georgia, USAa; Children’s Healthcare of Atlanta, Atlanta, Georgia, USAb; Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USAa; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USAa

Respiratory syncytial virus (RSV) is the leading cause of death due to a viral etiology in infants. RSV disease is characterized by epithelial desquamation, neutrophilic bronchiolitis and pneumonia, and obstructive pulmonary mucus. It has been shown that infection of BALB/cJ mice with RSV clinical isolate A2001/2-20 (2-20) results in a higher early viral load, greater airway necrosis, and higher levels of interleukin-13 (IL-13) and airway mucin expression than infection with RSV laboratory strain A2. We hypothesized that the fusion (F) protein of RSV 2-20 is a mucus-inducing viral factor. In vitro, the fusion activity of 2-20 F but not that of A2 F was enhanced by expression of RSV G. We generated a recombinant F-chimeric RSV by replacing the F gene of A2 with the F gene of 2-20, generating A2–2-20F. Similar to the results obtained with the parent 2-20 strain, infection of BALB/cJ mice with A2–2-20F resulted in a higher early viral load and higher levels of subsequent pulmonary mucin expression than infection with the A2 strain. A2–2-20F infection induced greater necrotic airway damage and neutrophil infiltration than A2 infection. We hypothesized that the neutrophil response to A2–2-20F infection is involved in mucin expression. Antibody-mediated depletion of neutrophils in RSV-infected mice resulted in lower tumor necrosis factor alpha levels, fewer IL-13-expressing CD4 T cells, and less airway mucin production in the lung. Our data are consistent with a model in which the F and attachment (G) glycoprotein functional interaction leads to enhanced fusion and F is a key factor in airway epithelium infection, pathogenesis, and subsequent airway mucin expression.
sion higher than those caused by RSV A2. Neutrophil depletion caused diminished airway mucin expression and TNF-α production during 2-20 infection. Our results elucidate a novel pathway of RSV pathogenesis whereby the F protein results in airway cell debris and the ensuing robust neutrophil response mediates TIPS cell IL-13 expression and airway mucin expression. Mechanistic characterization identified a unique functional interaction between the RSV attachment (G) glycoprotein and F protein that may be important for RSV fusion and pathogenesis.

**MATERIALS AND METHODS**

**Cells, viruses, and mice.** HEp-2 cells were obtained from the ATCC and propagated in minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS) and penicillin G-streptomycin sulfa-ampiphoterin B solution (Mediatech, Manassas, VA). 293T cells were obtained from the ATCC and propagated in MEM supplemented with 10% FBS and penicillin G-streptomycin sulfa-ampiphoterin B solution. The A2 strain of RSV was provided by Stokes Peebles (Vanderbilt, Nashville, TN) and maintained by passage in HEp-2 cells. The 2-20 RSV strain was maintained by passage in HEp-2 cells (13). Viral stocks were propagated and titrated by plaque assay in HEp-2 cells as described previously (13). Female 6-week-old BALB/c mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice were maintained under specific-pathogen-free conditions. Mice were anesthetized by intramuscular injection of ketamine-xylazine solution and infected intranasally (i.n.) with RSV stock or with mock-infected HEp-2 cell culture supernatant, as described previously (17). All animal procedures were conducted according to the guidelines of the Emory University Institutional Animal Care and Use Committee.

**Generation and recovery of chimeric A2–2-20F RSV.** Total RNA was isolated from HEp-2 cells infected with RSV strain 2-20. cDNA was reverse transcribed as described previously using primer F-r (16). PCR amplifications were gel purified and sequenced. The 2-20 F cDNA sequence from three separate infections was compared to the published 2-20 F sequence and confirmed (13). The F cDNA was then PCR amplified using forward primer FStul and reverse primer FSpil, which incorporated Stul and Spil restriction sites into the F-G intergenic region and F-M2 intergenic region, respectively, and also flanking EcoRI sites, as described previously (16). The 2-20 F cDNA was cloned into the EcoRI site of pGEM-9zf (Promega, Madison WI) and then moved, using Stul and Spil, into a low-copy-number subclone (pLG4) harboring an XhoI/BamHI fragment of RSV antigenic cDNA clone D46/6120 containing the RSV A2 G gene and the F gene flanked by Stul and Spil and the partial M2 sequence of RSV, thereby replacing the A2 F gene (16). The XhoI/BamHI fragment containing 2-20 F was then cloned into RSV antigenic cDNA plasmid D46/6120, yielding the full-length recombinant A2–2-20F plasmid, in which the sequence of the F gene was confirmed.

**BSR/T7/5 cells,** which constitutively express T7 polymerase (provided by Ursula J. Buchholz and Karl-Klaus Conzelmann), were transfected with A2–2-20F and four support plasmids which express RSV N, P, M2-1, and L proteins under the control of the T7 promoter (18, 19). Transfected cells were passed until syncytia were observed, at which point they were scraped into the medium, snap-frozen, thawed, and used to infect HEp-2 cells (16). When the maximal cytopathic effect was observed in HEp-2 cells, serial dilutions of clarified supernatants were used to infect fresh HEp-2 cells, which were overlaid with agarose-medium. Single plaques were picked and amplified in HEp-2 cells to generate viral stocks. The F cDNA was PCR amplified from the recovered working A2–2-20F virus stock as described above, and the F cDNA sequence was confirmed. The stock was confirmed to be mycoplasma free through PCR-based testing (Venor GeM mycoplasma detection kit, PCR based; Sigma-Aldrich, St. Louis, MO).

**Multistep virus growth curves.** Subconfluent HEp-2 cells in six-well dishes were infected in triplicate with RSV strain A2, 2-20, or A2–2-20F at a multiplicity of infection (MOI) of 1.0 in 250 μl. After 1 h of adsorption at room temperature on a rocking platform, the cells were washed with phosphate-buffered saline (PBS), and fresh medium was added. Supernatants were harvested from each well at 12 h, 24 h, 48 h, and 72 h, and RSV was titrated in duplicate by plaque assay on HEp-2 cells as described previously (13).

**Quantification of lung viral load.** BALB/c mice were infected with 10⁶ PFU of RSV, and lungs were harvested at the indicated time points. A BeadBeater apparatus (Biospec Products, Bartlesville, OK) was used to homogenize the lungs as previously described (13). Lung homogenates were serially diluted and used to inoculate subconfluent HEp-2 cells in 24-well dishes as described above and overlaid with MEM supplemented with 10% FBS, penicillin G-streptomycin sulfa-ampiphoterin B solution, and 0.75% methylcellulose (13). After 6 days, plates were visualized by immunodetection as described previously (13).

**Histopathology.** Lungs were fixed in 10% neutral buffered formalin for 24 h and then transferred to 70% ethanol. Lungs were then embedded in paraffin blocks, and 5-μm-thick tissue sections were cut and then stained with hematoxylin-eosin (H&E) to examine histologic changes. A pathologist blinded to the groups scored the samples for severity of infiltrates of lymphocytes, neutrophils, macrophages, and eosinophils on a scale of 0 from 0 to 4 for peribronchiolar, perivascular, interstitial, and alveolar spaces. Slides were scored for the presence or absence of bronchiolar exudates containing necrotic cell debris. Additional sections were also stained with periodic acid-Schiff (PAS) stain to quantify the amount of mucin expression in airways. PAS-stained slides were digitally scanned using a Mirax Midi microscope, and slides were analyzed for PAS-positive airways using HistoQuant software (3D Histotech, Budapest, Hungary), as we previously described (13). Each airway was outlined individually, and all airways in the section were included in the data.

**Dual-functional split-reporter (DSP) fusion assay.** An assay using fused split-reporter proteins Revilula luciferase (RL) and green fluorescent protein (GFP), which recover activity when they reassociate due to cell fusion, allows quantification of viral protein-induced cell-cell fusion (20). The GFP reporter protein is made up of a small fragment of GFP fragment harboring a β sheet (21). Transfected cells expressing DSP₁₋₇ or DSP₁ₑ₋₁₂ were used (22). Plasmids expressing cDNA codons optimized for mammalian expression (GeneArt; Invitrogen, Carlsbad, CA) of RSV A2 F, A2 G, 2-20 F, and 2-20 G were cloned into pcDNA3.1 (+) (Invitrogen), and the sequences were confirmed. 293T cells (90% confluent) were transfected with plasmids expressing A2 F, 2-20 F, 2-20 F and A2 G, 2-20 F and 2-20 G, or 2-20 F and A2 G plus DSP₁₋₇. Additional wells were transfected with plasmids expressing DSP₁ₑ₋₁₂. 293T cells were transfected with Lipo- fectamine 2000 (Invitrogen) and incubated in MEM with 10% FBS and 1% penicillin G-streptomycin sulfa-ampiphoterin B containing 250 nM RSV fusion inhibitor BMS–433771 (Allos Biopharma, San Francisco, CA) for 24 h at 37°C in 5% CO₂. At 24 h posttransfection, cells were washed with 1 ml PBS and resuspended in 1 ml medium containing 1:1,000 EnduRen live cell substrate (Promega, Madison, WI). Cells expressing DSP₁₋₇ as well as A2 F, 2-20 F, A2 F and A2 G, 2-20 F and 2-20 G, or 2-20 F and A2 G were mixed in an equal volume with cells expressing DSP₁ₑ₋₁₂. One hundred microliters of each cell mixture was plated in a white 96-well plate, and RL activity was measured with a Top Count luminometer (PerkinElmer, Waltham, MA) at the indicated time points.

**Western blotting of F and G levels in transfected 293T cells.** For immunoblotting, proteins were separated by SDS-PAGE, followed by transfer to a polyvinylidene difluoride membrane. After electroblocting, the membranes were probed using a SNAP i.d. system (Millipore, Billerica, MA). Briefly, the blot was saturated in 0.5% nonfat dry milk in Tris-buffered saline–Tween 20 (TBS-T). After blocking, the membrane was washed three times with TBS-T, followed by incubation with primary antibody against RSV F (palivizumab antibody, 1:1,000; a gift from James Crowe, Vanderbilt, Nashville, TN) or RSV G (131-2G; 1:5,000; Millipore, Billerica, MA) for 10 min. Membranes were washed three times and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse, 1:10,000; anti-human, 1:10,000; Sigma-Aldrich, St. Louis, MO).
Flow cytometry analysis of F and G surface levels in transfected 293T cells. 293T cells (90% confluent) were transfected with plasmids expressing A2 F, A2 G, 2-20 F, or 2-20 G in a pcDNA 3.1 vector and DSP F G, as in the dual split-protein fusion assay. Cells were incubated for 36 h at 32°C to limit syncytium formation. Cells were harvested and washed in PBS containing 2% FBS and 0.1% NaN3. Cells were stained with panleukocytosis or anti-RSV G antibody (131-2G; Millipore) at a concentration of 1:100. Samples were incubated at 4°C in the dark for 2 h. Cells were then washed in 2 ml PBS containing 2% FBS and 0.1% NaN3 and centrifuged for 5 min at 456 × g. F samples were stained with anti-human phycoerythrin (PE; SouthernBiotech, Birmingham, AL) or human IgG1, K isotype control (SouthernBiotech). G samples were stained with anti-mouse allophycocyanin (APC; G; RMG1-1; Biolegend, San Diego, CA) or mouse IgG2a, K isotype control (eBm12a; ebioscience, San Diego, CA). Cells were analyzed using an LSR II flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo software (Tree Star Inc., Ashland, OR).

Neutrophil depletion in BALB/Cj mice. Seven- to 8-week-old BALB/Cj mice were depleted of neutrophils with 1 mg anti-Ly6G (1A8; Bio X Cell) on days 0, 2, 4, and 6 postinfection. Control mice were treated with rat IgG2a isotype control (2A3; Bio X Cell) on days 2, 0, 2, 4, and 6 postinfection.

Flow cytometric analysis of blood cells. Blood was collected by submandibular bleed on days 1 and 7 postinfection Peripheral blood mononuclear cells (PBMCs) were isolated using erythrocyte lysis buffer (0.15 M potassium chloride, 10 mM KHCO3, 0.1 mM EDTA) and counted with a hemocytometer. Cells were stained with anti-CD11b (M1/70; ebioscience) and anti-Gr-1 (RB6-8C5; BD Biosciences). A total of 5 × 10^6 cells were analyzed using an LSR II flow cytometer (BD Biosciences). The total number of neutrophils was calculated by multiplying the percentage of CD11b+ Gr-1+ cells by the total number of cells isolated. Data were analyzed using FlowJo software (Tree Star Inc.).

Flow cytometric analysis of lung mononuclear cells. Mice were euthanized with sodium pentobarbitol (8.5 mg/kg body weight) i.p., and lungs were harvested at 1 and 8 days postinfection. Cells were isolated using Ficol and counted with a hemocytometer. Cells were stained with the following antibodies: anti-CD11b and anti-Gr-1 or anti-major histocompatibility complex class II (anti-MHC-II; M5/114.15.2; ebioscience), anti-CD11b (M1/70; ebioscience), and anti-Gr-1 (RB6-8C5; BD Biosciences). A total of 5 × 10^6 cells were analyzed using an LSR II flow cytometer (BD Biosciences). The total number of neutrophils was calculated by multiplying the percentage of CD11b+ Gr-1+ cells by the total number of cells isolated. Data were analyzed with FlowJo software (Tree Star Inc.).

Cytokine quantification. Cytokines in lung homogenates were analyzed by Lumixin bead analysis (Invitrogen) according to the manufacturer's protocol. Samples were centrifuged in a tabletop centrifuge at room temperature for 5 min, and 50 μl of sample was incubated with anti-body-coated capture beads for 2 h at room temperature. After washing the beads three times, protein-specific biotinylated detector antibodies were added and incubated with the beads for 1 h. After removal of excess biotinylated antibodies, streptavidin conjugated to a fluorescent protein, R-phycocerythrin (streptavidin-RPE), was added, and the mixture was incubated for 30 min. After washing of unbound streptavidin-RPE, the beads were analyzed with a Luminex 200 machine (Austin, TX).

Generation of prefusion RSV fusion protein model. Structural models are based on the recently reported coordinates of the RSV F protein in its prefusion conformation (Protein Data Bank [PDB] accession number 4JHW) (23). The UCSF chimera (24) and MacPyMol programs were used for structure analysis and presentation.

RESULTS

RSV A2–2-20F replication in human cells and viral load in BALB/Cj mice. RSV strain 2-20 infection causes airway mucin expression in BALB/Cj mice (13). The fusion (F) protein of the mucus-inducing RSV strain 19 was shown to be a factor in airway mucin expression induced by RSV infection in BALB/Cj mice (16). We hypothesized that the 2-20 F protein may similarly be a mucin-inducing factor in RSV infection. We generated a chimeric RSV strain that contains the 2-20 gene in an RSV A2 genetic background (RSV A2–2-20F). We first compared the in vitro growth of RSV A2–2-20F to that of RSV A2 and RSV 2-20. In HEp-2 cells, RSV A2–2-20F grew to lower titers (P < 0.05, ANOVA) than its parent strains at 48 h postinfection, and there were no significant differences between strains at any other time points (Fig. 1A). BALB/Cj mice are semipermissive for RSV replication. We previously showed that RSV 2-20 exhibits a higher viral load on day 1 postinfection and a lower peak viral load than RSV A2 (13). The viral loads of RSV strains A2, 2-20, and A2–2-20F were compared over a time course. BALB/Cj mice were infected with 10^5 PFU of each strain. RSV A2–2-20F and 2-20 had significantly higher viral loads than A2 on day 1 postinfection, although these titers were near the limit of detection of the plaque assay. RSV A2 had a significantly higher viral load on days 4 and 6 postinfection (Fig. 1B), and A2 grew to a higher peak titer in vivo. However, early viral load differences may play a role in RSV pathogenesis in BALB/cj mice. The similar viral loads of 2-20A and A2–2-20F show that the 2-20 F gene is a determinant of the viral load.

RSV A2–2-20F causes early lung lesions in BALB/Cj mice. Lung injury is common in severe RSV infection, shown by loss of lung epithelial cells, edema, hemorrhage, and alveolar inflammation (25). Lung damage is thought to be mediated by both direct effects of the virus and the immune response (26). We previously reported that RSV 2-20 infects the airway epithelium at 1 day postinfection in mice (13). We sought to determine if early viral load correlates with early lung lesion development in RSV A2–2-20F-infected mice. At day 1 postinfection, mice infected with RSV A2–2-20F exhibited increased interstitial pneumonia involving increased thickening of alveolar walls associated with inflammatory cell infiltrates compared to mock-infected and RSV A2-infected mice (Fig. 2A and B). RSV 2-20-infected mice also had significantly more interstitial pneumonia than mock-infected mice (Fig. 2A and B). There was no difference in the interstitial pneumonia scores between groups on day 4, 6, or 8 postinfection (data not shown). The airways of RSV 2-20- and A2–2-20F-in-
fected mice contained more necrotic cell debris than mock- and A2-infected mice on day 1 postinfection (Fig. 2C). One of 10 mock-infected mice and 1 of 10 A2-infected mice exhibited airway necrotic cell debris. In contrast, necrotic cell debris was observed in 6 of 10 mice infected with RSV 2-20 and 8 of 10 mice infected with RSV A2–2-20F. Epithelial cell debris and BAL fluid cells in the airways of infected mice reportedly contribute to the pathogenesis of RSV (23). Our data show that A2–2-20F-infected mice

FIG 1 In vitro growth and in vivo viral load of RSV strains A2, 2-20, and A2–2-20F. (A) Infectious yield in supernatants of HEp-2 cells infected at an MOI of 1.0 with RSV A2, 2-20, or A2–2-20F. Error bars represent SEMs of two replicates. Data are means ± SEMs. *, the infectious yield of A2 was significantly higher than that of A2–2-20F at 48 h postinfection (P < 0.05, ANOVA). The results shown represent those from three experiments with similar data. (B) BALB/cJ mice were infected with 5 × 10⁶ PFU of A2, 2-20, or A2–2-20F (n = 5/group). Lungs were harvested on the indicated days postinfection, and infectious RSV was titrated by plaque assay. Data are means ± SEMs. *, at day 1 postinfection, values for 2-20 and A2–2-20F were significantly higher than those for A2 (P < 0.05, ANOVA); **, at day 4 postinfection, the value for A2 was significantly higher than the values for 2-20 and A2–2-20F (P < 0.05, ANOVA). Dashed line, limit of detection. The results shown represent those for three experiments with similar data.

FIG 2 RSV A2–2-20F infection results in early lung lesions in BALB/cJ mice. BALB/cJ mice were mock infected or infected with 10⁵ PFU of the indicated strain. Lungs were harvested on day 1 postinfection, stained with H&E, and analyzed for histologic changes. (A) Interstitial pneumonia (IP) score for each group. *, significant difference from mock-infected animals (P < 0.01, ANOVA); **, significant difference from mock- and A2-infected animals (P < 0.05, ANOVA). (B) Representative airways indicating interstitial pneumonia in mock-, A2-, 2-20-, and A2–2-20F-infected mice. (C) Representative airways containing cell debris in mock-, A2-, 2-20-, and A2–2-20F-infected mice. The results shown represent those from two experiments with similar data.
exhibit lung epithelial damage and inflammation on day 1 postinfection.

**RSV A2–2-20F infection causes airway mucin expression.** Pulmonary mucus expression is a hallmark of severe RSV disease in infants (27). RSV 2-20 infection of BALB/cJ mice triggers higher airway mucin expression than infection with RSV A2 (13). We used the chimeric virus RSV A2–2-20F to determine whether the 2-20 F protein is responsible for this phenotype. Periodic acid-Schiff (PAS) staining was used to examine the mucin distribution in the airways of RSV-infected mice. Mice were infected with 10^5 PFU of RSV, and lungs were harvested on day 8 postinfection. Both 2-20- and A2–2-20F-infected mice exhibited significantly greater PAS positivity than mock- and A2-infected mice (Fig. 3). Greater than 5% of the airways in 2-20- and A2–2-20F-infected mice had approximately 10% mucin positivity, whereas approximately 1% of the airways in A2-infected mice had such mucin positivity (Fig. 3). These results show that both 2-20 infection and A2–2-20F infection result in more airway mucin expression in the airways of BALB/cJ mice than A2 infection, suggesting that the 2-20 F protein is a mucus-inducing factor in RSV infection.

**Fusion activity.** We sought to determine the underlying mechanisms of 2-20 F-protein-mediated pathogenesis. We hypothesized that the 2-20 F protein has greater fusion activity than the A2 F protein. To quantitate cell-to-cell fusion, we used a bioluminescence reporter-based content mixing assay (20). 293T cells were transfected with A2 F, 2-20 F, A2 F and A2 G, 2-20 F and 2-20 G, or 2-20 F and A2 G plus DSP1-7 and mixed with 293T cells transfected with DSP8-11. An RSV fusion inhibitor, BMS-433771, was used during transfection to eliminate effector cell-to-effector cell fusion. This inhibitor was removed prior to cell mixing to allow...
effector cell-to-target cell fusion. Transfected cells expressed total cell (Fig. 4A and B) and surface (Fig. 4C and D) levels of F and G proteins equivalently. Contrary to our hypothesis, A2 F and 2-20 F had equal fusion activity (Fig. 4E and F). It has been shown that coexpression of the RSV attachment (G) glycoprotein promotes fusion (28). We therefore also tested whether RSV A2 G and/or 2-20 G can enhance fusion. Both G proteins increased the fusion activity of 2-20 F but not that of A2 F. RSV F and G glycoproteins interact to form a complex on the surface of infected cells, suggesting that G plays a role in RSV fusion (29). We identified a specific, functional interaction between 2-20 F and RSV G.

**RSV A2–2-20F infection results in lung neutrophil recruitment in BALB/cJ mice.** Neutrophils are present in the lungs of children with severe RSV infection (9, 30). Additionally, neutrophils are among the first cells to be recruited to the site of infection and have been shown to contribute to cell damage (11, 31). H&E staining revealed neutrophil infiltration in the lungs of A2–2-20F-infected mice (data not shown). We used flow cytometry to determine neutrophil levels in the lungs of infected BALB/cJ mice on day 1 postinfection and found significantly higher levels in the lungs of A2–2-20F–infected BALB/cJ mice than in those of mock- and A2-infected mice (Fig. 5). Thus, the 2-20 F protein contrib-
utes to pulmonary neutrophil recruitment. 2-20-infected mice showed an intermediate phenotype with higher neutrophil levels than in A2-infected mice but slightly less than in A2-2-20F-infected mice (Fig. 5). There are many sequence differences between the 2-20 and A2 genomes (GenBank accession numbers M74568 and JX069798, respectively), but the A2–2-20F recombinant narrows the candidate pool to residues within the F protein. A2–2-20F permits the analysis of the 2-20 F protein specifically.

**Neutrophil depletion in RSV-infected BALB/cJ mice.** Anti-Ly6G clone monoclonal antibody 1A8 has been shown to be specific for neutrophils (32). BALB/cJ mice were treated with anti-Ly6G in order to investigate the role of neutrophils in the context of RSV-induced airway mucin expression. Lung and peripheral blood mononuclear cells were isolated from mock- and RSV-infected mice that were treated with anti-Ly6G or IgG2a isotype control antibody. Administration of this anti-Ly6G antibody in the context of RSV infection resulted in depletion of neutrophils for the duration of infection in both the blood and lungs of BALB/cJ mice (Fig. 6). Mock-infected mice had greater numbers of neutrophils in the lung on day 1 than day 7 postinfection, indicating that the mock preparation does induce an early neutrophil response in the lung (Fig. 6G and H). The macrophage population in anti-Ly6G-treated mice was also investigated. The levels of MHC-II+ Gr-1+ CD11b+ cells were not significantly affected by antibody treatment (Fig. 7). Eosinophils do not express Ly6G and therefore are not affected by 1A8 antibody treatment (32).

To assess the contribution of neutrophils to RSV clearance, we examined the viral loads in neutrophil-depleted and isotype control-treated BALB/cJ mice. Though neutrophil-depleted mice had a slightly higher viral load on days 4, 6, and 8 postinfection, this difference never reached significance (Fig. 8). These results show that neutrophils do not contribute to viral clearance in this RSV infection model.

**Neutrophil depletion during RSV infection modulates airway mucin expression.** Neutrophils have been shown to be associated with lung mucus in models such as those for chronic obstructive pulmonary disease and asthma (23, 24). We hypothesized that neutrophils also modulate mucin expression in the lungs of RSV-infected mice. To examine this, lungs were harvested on day 8 postinfection from mock- or RSV-infected mice treated with anti-Ly6G or isotype control antibody and stained with PAS. Neutrophil depletion in RSV-infected mice resulted in significantly more PAS-positive airways than in RSV-infected isotype control-treated mice (Fig. 9). These data indicate that neutrophils play a role in airway mucin expression during pathogenic RSV 2-20 infection.

**Neutrophil depletion in the setting of RSV infection decreases lung TNF-α levels.** TNF-α is a cytokine that has been linked to mucus production. Intratracheal administration of TNF-α to BALB/cJ mice was shown to induce mucus production (12). Because activated neutrophils release TNF-α, we postulated that depletion of neutrophils would result in less TNF-α in the lungs (33). Indeed, RSV-infected mice treated with anti-Ly6G antibody had significantly decreased TNF-α levels in the lungs on day 1 postinfection (Fig. 10). This decrease coincided with a decrease in neutrophil levels in the lungs due to antibody depletion.

**Neutrophil depletion during RSV infection results in fewer pulmonary IL-13+ CD4 T cells in depleted mice than in control mice.** IL-13 is a key factor that mediates mucus production in the lungs (15, 34, 35). This cytokine is necessary for both RSV line 19- and 2-20-induced PAS positivity (13, 16). We previously showed that RSV 2-20 infection results in greater IL-13 production than RSV A2 infection (13). Here, we sought to determine a cell source of IL-13 in the RSV infection model and define the effect of neutrophil depletion on IL-13 production. IL-13-producing CD4 T cells were quantified on day 6 postinfection. Neutrophil depletion did not affect the number of lung CD4+ T cells or CD8+ T cells (data not shown) but resulted in fewer IL-13+ CD4 T cells than in isotype control-treated mice (Fig. 11). These CD4+ T cells are likely an important source of IL-13 that causes mucin expression during RSV infection. Our data show that neutrophils modulate CD4 T cell IL-13 expression in RSV infection.

**DISCUSSION**

Using a genetically controlled chimeric virus approach, we have shown that the F protein of RSV 2-20 increases the pathogenicity...
FIG 6 Anti-Ly6G treatment results in depletion of neutrophils in the blood and lungs of RSV-infected mice. BALB/cJ mice were treated with IgG2a control antibody or anti-Ly6G antibody. These mice were mock infected or infected with 1 × 10^6 PFU RSV 2-20. Blood was taken at days 1 and 7 postinfection. Lungs were harvested on days 1 and 8 postinfection. Cells were isolated by use of a Ficoll gradient and stained for CD11b and Gr-1. (A) Representative flow plots of PBMCs from the indicated group on day 1 postinfection. (B) Representative flow plots of PBMCs from the indicated groups on day 7 postinfection. (C) Quantification of PBMCs on day 1. Results are representative of those from three replicate experiments. (D) Quantification of PBMCs on day 7. Results are representative of those from three replicate experiments. (E) Representative flow plots of lung cells from the indicated group on day 1 postinfection. (F) Representative flow plots of lung cells from the indicated group on day 8 postinfection. (G) Quantification of lung cells on day 1. Results are representative of those from three replicate experiments. (H) Quantification of lung cells on day 8. Results are representative of those from three replicate experiments. Bars, significant differences (P < 0.05, ANOVA).
of the laboratory strain A2, as evidenced by greater interstitial pneumonia, increased mucin levels, and more necrotic cell debris in the airways. An increased early viral load correlated with airway necrotic cell debris. Additionally, infection with RSV A2–2-20F resulted in greater neutrophil infiltration into the lungs of BALB/cJ mice than mock and A2 infection. Our data show that neutrophils play an important immunomodulatory role in RSV infection. Depletion of neutrophils had no effect on viral load but resulted in less airway mucin expression, lower lung TNF-α levels, and fewer IL-13-producing CD4+ T cells compared to the findings for isotype control antibody-treated animals during RSV infection. Therefore, neutrophils contribute to pulmonary mucus expression and RSV pathogenesis, potentially through modulation of TNF-α expression and IL-13 expression by CD4+ T cells.

It was previously shown that the fusion protein of RSV strain line 19 is a factor that plays a role in pulmonary mucin expression in the setting of RSV infection (16). BALB/cJ mouse infection with chimeric A2-line 19F resulted in a peak viral load higher than that achieved with infection with the parent viruses A2 and line 19 (16). The unique amino acids in RSV line 19 F, however, are not found in any clinical isolates of RSV (Hotard and Moore, unpublished). The passage history of the line 19 strain is unclear and included many passages through human embryonic diploid lung (MRC-5) cells (36). On the other hand, 2-20 is a clinical isolate with a defined low number of passages (13). Unlike A2-line 19F, A2–2-20F had a viral load pattern similar to that of parent virus

![Image](image1.png)

**FIG 7** 1A8 administration does not affect macrophage numbers in mock- or RSV-infected mice. BALB/cJ mice were treated with IgG2a isotype control antibody or anti-Ly6G antibody. These mice were mock infected (n = 3 or 5 per group) or infected with 1 × 10^6 PFU of 2-20 (n = 3 or 5). Lungs were harvested at day 6 postinfection. Cells were isolated by the use of a Ficoll gradient and stained for MHC-II and CD11b. Data were analyzed using FlowJo software. (A) Representative flow plots gated for MHC-II+CD11b+ cells; (B) quantification of three replicates.

![Image](image2.png)

**FIG 8** Viral load after neutrophil depletion. BALB/cJ mice were treated with IgG2a isotype control antibody or anti-Ly6G antibody. BALB/cJ mice were mock infected (n = 5) or infected with 1 × 10^6 PFU of 2-20 (n = 5). Lungs were harvested on the indicated days, and infectious RSV was titrated by an immunodetection plaque assay. Solid line, limit of detection. Data represent the results of three replicate experiments.

![Image](image3.png)

**FIG 9** Neutrophil depletion decreased mucin production. BALB/c mice were treated with IgG2a isotype control antibody or anti-Ly6G antibody. These mice were mock infected (n = 5 per group) or infected with 1 × 10^6 PFU of 2-20 (n = 5). Lungs were harvested at 8 days postinfection and processed for PAS staining. Data show the percentage of the area that was PAS positive for each airway; >200 individual airways are shown per group. Each symbol represents one airway. *, significant differences from other groups (P < 0.05, ANOVA). Data represents the results from two replicate experiments.
2-20. This suggests that although infection of BALB/cJ mice with both line 19 and 2-20 induces pulmonary mucin expression, the underlying mechanisms leading to its phenotype are distinct. Our data show that both 2-20 and A2–2-20F infection results in early (day 1) lung debris in the airway epithelium of BALB/cJ mice. We hypothesize that this early damage affects the subsequent immune response and results in mucus production. We previously showed that RSV 2-20 viral antigen is detectable in the airway epithelium on day 1 postinfection (13), while at 4 days postinfection viral antigen is localized to the alveolar region (37). Our data are consistent with a model in which 2-20 F renders the mouse airway epithelium susceptible to infection. Infection of the airway epithelium results in necrosis, neutrophil recruitment, and subsequent mucin expression.

Although RSV F can trigger fusion without G, its cognate attachment protein, our data suggest that G and F interaction promotes fusion. Activation of most Paramyxovirinae subfamily F proteins involves interaction with the attachment protein (38). In an in vitro fusion assay, 2-20 F was more fusogenic than A2 F when it was coexpressed with either A2 G or homotypic 2-20 G protein. These data suggest that RSV G boosts 2-20 F fusion activity, but the precise mechanism is unknown. The F and G proteins likely interact to form a complex on the surface of infected cells (29). Hydrophobic residues located in the lower half of the head of the measles virus (MeV) F protein were shown to be important for fusion and interactions with the MeV attachment protein (39). We hypothesize that this increased fusion activity due to 2-20 F affects subsequent RSV pathogenesis. In previous studies, infection of both primary and immortalized human airway epithelial cells did not result in obvious syncytium formation (40, 41). Cell-to-cell fusion, however, was observed in recent studies performed in well-differentiated pediatric bronchial epithelial cells (WD-PECs) cultured at an air-liquid interface (42). Interestingly, more syncytia were observed in WD-PECs infected with an RSV clinical isolate than in WD-PECs infected with the RSV A2 strain (42). Cell-to-cell fusion was also seen in WD-PECs after infection with Sendai virus (SeV) (43). It has been shown that specific residues in the fusion protein of SeV modulate its virulence by influencing both the spread of the virus and the severity of inflammation (44).

There are 15 amino acid differences between the structures of the RSV A2 and 2-20 fusion proteins (Fig. 12). Residues 4, 8, 16, 20, and 25 are not present in the protein because they are part of the signal peptide that directs the F0 precursor to the endoplasmic reticulum. Residue 124 is present in the short, 27-residue peptide between the furin cleavage sites. Of the remaining residues, mu-
The relationship between viral load and disease in RSV pathogenesis is not defined. A previous study indicated that higher viral loads in infants are a predictor of greater disease severity (49, 50). Other studies, however, have shown no correlation between viral titers and disease severity (51, 52). In the mouse model of 2-20 and A2-2-20F infection, pathogenesis correlated with the early viral load and not the peak viral load. The cell tropism of clinical RSV A2–2-20F infection, pathogenesis correlated with the early viral titers and disease severity (51,52). In the mouse model of 2-20 and A2 infection also resulted in less necrotic cell debris and a drop in IL-13 expression by neutrophils (67) and is necessary for mucus production (68). It has been shown that RSV infection promotes a T H 2-type inflammatory response in the lung, subsequently inducing a T H 2-like effector phenotype in regulatory T cells and increasing susceptibility to asthma (69). BALB/cJ mouse infection with mucus-inducing RSV strains line 19 and 2-20 results in lung IL-13 expression (13, 14, 16). Neutrophils are seen in BAL fluid samples from severe asthmatics but not from mild or moderate asthmatics (70). In a model of allergic asthma, IL-13 was shown to activate neutrophils (67, 71). It was also found that IL-13 administration induced substantial airway neutrophilia (72). In neutrophil-depleted, RSV-infected BALB/cJ mice, there was a drop in IL-13 CD4 T cells compared to their levels in isotype-treated, RSV-infected mice. These results indicate that although IL-13 has been shown to act on neutrophils, neutrophils also modulate the IL-13 cellular immune response. Further elucidation of this pathway involving IL-13 and TNF-α may lead to therapies to combat RSV infection-induced pulmonary mucus.

Neutrophils have long been associated with bronchiolitis. For the first time, we analyzed the role of neutrophils in a mouse model of RSV bronchiolitis. We have identified a novel pathway wherein the F protein affects the early immune response to RSV, including the neutrophil response, and subsequently influences downstream cytokine and mucus expression. Our data suggest that the early viral load and damage influenced by the activity of the RSV F protein are related to the neutrophil and mucus responses.

ACKNOWLEDGMENTS
This work was supported by the following grants: NIH 1R01AI087798 and NIH 1U19AI095227.
We thank the Emory Children’s Pediatric Research Center flow cytometry core and immunology core, which are supported by Children’s Healthcare of Atlanta (CHOA). We thank Naoyuki Kondo and Zene Matsuda for the DSP1,7 and DSP1,11 plasmids and Ursula Buchholz and Karl-Klaus Conzelmann for the BSRT7/5 cells. We thank James Crowe, Jr., for palivizumab. We also thank Carla Shoaff for histology technical assistance.

REFERENCES


